Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SR147778 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SR147778 | DRUG | - |
Inclusion Criteria: * Patients must voluntarily sign the informed consent, * Patients must be male or female and aged 18 to 65 years, * Patients must be able to follow verbal and written instructions, * Female patients of childbearing potential (pre-menopausal women) must have a confirmed negative ...
Top 20 of 32 competitors
SR147778 is an investigational small molecule being developed for the treatment of obesity. It is intended for use in obese patients, as studied in a clinical trial evaluating its efficacy and safety. The drug is not yet approved and remains in clinical development.
SR147778 is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the drug's efficacy and safety in obese patients.
SR147778 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 2 trial has been completed to assess its efficacy and safety in obese patients.
SR147778 has one completed Phase 2 clinical trial, identified as NCT00239174. This multicenter study evaluated the efficacy and safety of four doses of SR147778 in 394 obese patients across Argentina, Australia, Finland, France, and Spain.
SR147778 is not known to have any alternative names. It is a distinct investigational compound developed by Sanofi for obesity, and no other names have been associated with it in clinical trial records.